logo

Biopharmx Corp (BPMX)



Trade BPMX now with
  Date
  Headline
12/10/2019 4:08:24 PM BioPharmX Q3 Loss/share $0.14 Vs. Loss $0.57 Year Ago
9/20/2019 4:12:31 PM BioPharmX Receives Notice Of Compliance Deadline Extension From NYSE American
9/9/2019 8:19:54 AM BioPharmX Q2 Net Loss $2.6 Mln Or $0.22/shr Vs. Net Loss Of $4.4 Mln Or $0.58/shr Prior Year
7/16/2019 4:19:44 PM BioPharmX Appoints Steven Bosacki As Chief Operating Officer
6/25/2019 7:31:41 AM BioPharmX Announces Positive Topline Results From Phase 2b Trial Of BPX-04 For Papulopustular Rosacea
6/11/2019 4:12:29 PM BioPharmX Q1 Loss/share $0.38 Vs. Loss $0.61 Year Ago
5/22/2019 8:11:11 AM BioPharmX Reports Last Patient Visit In Phase 2b Trial Of BPX-04 For Papulopustular Rosacea
4/26/2019 7:34:35 AM BioPharmX Completes 1-for-25 Reverse Stock Split
4/26/2019 7:30:00 AM BioPharmX Completes 1-for-25 Reverse Stock Split (Press Release)
3/14/2019 4:15:22 PM BioPharmX Q4 Loss/share $0.02 Vs. Loss $0.03 Year Ago
3/4/2019 6:03:18 AM BioPharmX Completes Enrollment In Phase 2b Trial Of BPX-04 For Patients With Papulopustular Rosacea
2/4/2019 7:10:01 AM BioPharmX Appointsof Veteran Pharmaceutical Developer Todd Plott As Independent Director
12/6/2018 4:23:07 PM BioPharmX Q3 Loss/share $0.02 Vs. Loss $0.05 Year Ago
11/16/2018 6:02:49 AM BioPharmX Announces NYSE American Acceptance Of Plan To Regain Listing Compliance
8/30/2018 4:20:11 PM BioPharmX Q2 Loss/share $0.02 Vs. Loss $0.05 Year Ago
7/31/2018 9:16:14 AM BioPharmX Gets IRB Approval To Begin Phase 2 Trial Of BPX-04 For Treatment Of Rosacea
7/19/2018 9:16:41 AM BioPharmX Secures FDA Grant Of CARC Waiver And Post-Hoc Analysis For BPX-01
  
 
>